Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Anika Therapeutics (ANIK) Equity Average: 2010-2024

Historic Equity Average for Anika Therapeutics (ANIK) over the last 15 years, with Dec 2024 value amounting to $183.1 million.

  • Anika Therapeutics' Equity Average fell 24.53% to $147.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $147.2 million, marking a year-over-year decrease of 24.53%. This contributed to the annual value of $183.1 million for FY2024, which is 26.43% down from last year.
  • According to the latest figures from FY2024, Anika Therapeutics' Equity Average is $183.1 million, which was down 26.43% from $248.9 million recorded in FY2023.
  • Anika Therapeutics' Equity Average's 5-year high stood at $286.3 million during FY2022, with a 5-year trough of $183.1 million in FY2024.
  • For the 3-year period, Anika Therapeutics' Equity Average averaged around $239.5 million, with its median value being $248.9 million (2023).
  • In the last 5 years, Anika Therapeutics' Equity Average grew by 2.35% in 2022 and then fell by 26.43% in 2024.
  • Anika Therapeutics' Equity Average (Yearly) stood at $280.4 million in 2020, then declined by 0.23% to $279.7 million in 2021, then increased by 2.35% to $286.3 million in 2022, then dropped by 13.07% to $248.9 million in 2023, then decreased by 26.43% to $183.1 million in 2024.